



Published in final edited form as:

Am J Obstet Gynecol. 2020 May ; 222(5): 471.e1–471.e9. doi:10.1016/j.ajog.2019.10.008.

Associations between the vaginal microbiome and *Candida* colonization in women of reproductive age

Mr. Brett A. TORTELLI, B.A.^{1,2}, Warren G. LEWIS, Ph.D.², Jenifer E. ALLSWORTH, Ph.D.⁶, Mr. Nadum MEMBER-MENEH, B.S.^{2,3}, Ms. Lynne R. FOSTER, B.S.^{2,3}, Hilary E. RENO, M.D. Ph.D.⁴, Jeffrey F. PEIPERT, M.D., Ph.D.⁷, Justin C. FAY, Ph.D.^{1,8}, Amanda L. LEWIS, Ph.D.^{2,3,5}

¹Department of Genetics, Washington University School of Medicine, St. Louis, MO, USA.

²Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, MO, USA.

³Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.

⁴Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA.

⁵Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA.

⁶Department of Biomedical and Health Informatics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.

⁷Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA.

⁸Department of Biology, University of Rochester, Rochester, NY, USA.

Abstract

Background: The composition of bacteria within the vaginal microbiome has garnered a lot of recent attention and has been associated with reproductive health and disease. Despite the common occurrence of yeast (primarily *Candida*) within the vaginal microbiome, there is still an incomplete picture of relationships between yeast and bacteria (especially lactobacilli), as well as how such

Amanda L. Lewis, Ph.D., Washington University School of Medicine, Department of Molecular Microbiology, 660 South Euclid Ave, Saint Louis, MO, 63119, Office phone: 314-286-0016, allewis@wustl.edu, Justin C. Fay, Ph.D., University of Rochester, Department of Biology, 319 Hutchison Hall, Rochester, NY 14627-0211, Office phone: 585-275-2998, justin.fay@rochester.edu.

Conflicts of interest: Dr. Peipert serves on advisory boards for Bayer and CooperSurgical, and has received research support from Merck, Bayer, and CooperSurgical/Teva. Although not directly related to the work, A. L. L. received personal (consulting) fees from companies involved in making diagnostics or treatments for bacterial vaginosis (Talis Biomedical Corporation, Tennon Therapeutics, and Toltec Pharmaceuticals) and both Dr. AL and WG Lewis have performed research sponsored by Metis Therapeutics and Metrodora Therapeutics. Remaining authors report no conflict of interest.

Paper presentation information: This manuscript was presented in part at the 14th ASM Conference on *Candida* and Candidiasis in Providence RI, April 15–19th 2018 and the American Physician Scientist Association 15th Annual Meeting in Chicago IL, April 5–7th 2019.

Condensation: *Lactobacillus iners*-dominant vaginal microbiomes are more likely to harbor vaginal *Candida* than *Lactobacillus crispatus*-dominant vaginal microbiomes.

associations are governed. Such relationships could be important to a more holistic understanding of the vaginal microbiome and its connection to reproductive health.

Objective: To perform molecular characterization of clinical specimens to define associations between vaginal bacteria (especially *Lactobacillus* species) and *Candida* colonization. *In vitro* studies were conducted to test the two most common dominant *Lactobacillus* species (*Lactobacillus crispatus* and *Lactobacillus iners*) in their ability to inhibit *Candida* growth and to examine the basis for such inhibition.

Study Design: A nested cross-sectional study of reproductive age women from the Contraceptive CHOICE Project was conducted. Vaginal swabs from 299 women were selected to balance race and BV status, resulting in similar representation of black and white women in each of the three Nugent score categories [normal (0–3), intermediate (4–6), and bacterial vaginosis (7–10)]. Sequencing of the 16S ribosomal gene (V4 region) was used to determine the dominant *Lactobacillus* species present (primarily *L. iners* and *L. crispatus*), defined as >50% of the community. Subjects without dominance by a single *Lactobacillus* species were classified as Diverse. A *Candida*-specific qPCR targeting the internally transcribed spacer 1 (ITS1) was validated using vaginal samples collected from a second cohort of women and used to assess *Candida* colonization. 255 nonpregnant women with sufficient bacterial biomass for analysis were included in the final analysis. Generalized linear models were employed to evaluate associations between *Lactobacillus* dominance, sociodemographic and risk characteristics and vaginal *Candida* colonization. In separate *in vitro* studies, the potential of cell-free supernatants from *L. crispatus* and *L. iners* cultures to inhibit *Candida* growth was evaluated.

Results: Forty-two women (16%) were vaginally colonized with *Candida*. Microbiomes characterized as Diverse (38%), *L. iners*-dominant (39%), and *L. crispatus*-dominant (20%) were the most common. The microbiome, race and *Candida* colonization co-varied with a higher prevalence of *Candida* among black women and *L. iners*-dominant communities compared to white women and *L. crispatus*-dominant communities. *L. iners*-dominant communities were more likely to harbor *Candida* than *L. crispatus*-dominant communities (OR = 2.85, 95% CI: 1.03 to 7.21; Fisher's Exact, p = 0.048). *In vitro*, *L. crispatus* produced greater concentrations of lactic acid and exhibited significantly more pH-dependent growth inhibition of *C. albicans*, suggesting a potential mechanism for the clinical observations.

Conclusion: In nonpregnant women, *L. iners*-dominant communities were significantly more likely to harbor *Candida* than *L. crispatus*-dominant communities, suggesting that *Lactobacillus* species have different relationships with *Candida*. *In vitro* experiments indicate that *L. crispatus* may impede *Candida* colonization more effectively than *L. iners* through a greater production of lactic acid.

Keywords

vaginal microbiome; *Candida*; *Lactobacillus*; race; pH

Introduction

The human vagina is a dynamic ecosystem that hosts microbes from diverse taxa. Profiling 16S ribosomal gene diversity has expanded our understanding of the vaginal microbiome,

allowing exploration of links between bacterial composition and reproductive outcomes. Vaginal microbial communities can be clustered into five common community types.¹ Four of these are dominated by a single *Lactobacillus* species: *L. crispatus*, *L. gasseri*, *L. iners*, or *L. jensenii*. The final community type (often described as “Diverse”) has few lactobacilli and exhibits greater representation of anaerobic bacteria such as *Gardnerella vaginalis*, *Atopobium vaginae* and *Prevotella spp.*¹ The prevalence of these community types varies with race and ethnicity; black and Hispanic women more frequently host *L. iners*-dominant and Diverse communities than white women, who more frequently host *L. crispatus*-dominant communities.^{1,2} Diverse communities often harbor bacterial taxa that are abundant during bacterial vaginosis (BV), a condition diagnosed by clinical (Amsel) criteria or by Nugent scoring,³ a 0–10 scale generated by scoring bacterial morphotypes in Gram-stained vaginal smears (0–3, normal; 4–6, intermediate; 7–10, BV). BV is associated with increased risks of sexually transmitted infections and adverse reproductive outcomes.⁴

Candida (most commonly *C. albicans*) is a common member of the vaginal microbiome (found in ~30% of women⁵). The prevalence of non-*albicans* species among women with vaginal *Candida* varies, ranging from ~10–30%.^{5–9} Vaginal *Candida* colonization may lead to vulvovaginal candidiasis (VVC), characterized by an aggressive host response to *Candida* overgrowth.¹⁰ However, *Candida* colonization is frequently asymptomatic and not all women colonized with *Candida* go on to experience VVC.⁵ Vaginal *Candida* colonization has also been linked to other adverse reproductive outcomes.^{8,11–16}

Several prior studies have examined relationships between vaginal bacteria and *Candida*. A few of these studies implicate an abundance of lactobacilli with a greater likelihood of harboring *Candida*.^{5,6,17} Other studies suggest there may be co-occurrence of *Candida* with some BV-associated bacteria,^{18–21} and specifically that *Candida* may be correlated with the simultaneous presence of both lactobacilli and BV-associated bacteria.^{19–21} An important limitation is that prior studies, whether using molecular or culture-based techniques, have not distinguished between lactobacilli at the species level. This is a significant limitation, which if resolved, may shed light on why some women are so prone to *Candida* colonization and candidiasis.

Taken together with the prior studies above, several considerations led us to hypothesize that *L. iners* in particular may support the co-occurrence of *Candida*, especially compared to *L. crispatus*. *L. iners* is unique among the lactobacilli in being prevalent within less stable Nugent intermediate and BV communities^{1,22,23} and in producing a cytolytic toxin.^{24,25} Furthermore, *L. iners* dominance has been associated with other negative health outcomes such as increased risks of *Chlamydia trachomatis* infection,²⁶ incident BV,²⁷ defects in vaginal mucus that compromise antiviral barrier function,²⁸ and cytokine signatures linked with HIV risk.²⁹ We performed two types of studies to test our hypothesis that *L. iners* may preferentially support *Candida* colonization 1) a molecular evaluation of clinical specimens, and 2) *in vitro* growth inhibition studies.

Methods

Study design:

This nested cross-sectional study uses samples and questionnaire data collected by the Contraceptive CHOICE Project (CHOICE)³⁰ according to Washington University IRB-approved protocol 201108155. In total, 9256 women from the St. Louis-area gave informed consent from August 2007 through September 2011. For this nested study, 299 women enrolled from 08/2008–06/2009 were selected based on power calculations made from preliminary data. Women enrolled in the CHOICE study were between the ages of 14 and 45, reported sexual activity in the past six months or anticipated sexual activity with a male partner and were seeking contraception. Women with a history of tubal ligation or hysterectomy were excluded. All women underwent a pregnancy test. Vaginal swab specimens were self-collected in the vast majority of cases, then stored at –80°C until analysis. Of the swabs used in the final analysis, one was collected by a clinician and the collection method was missing for five samples.

Women who completed a baseline survey (including Sociodemographic data) and had a vaginal swab available were eligible for inclusion. Samples from all participants underwent Nugent scoring to determine BV status.^{3,31,32} Unfortunately, vaginal pH and data regarding menstrual cycle and recent sexual activity was only available for a subset of women and were inadequate for analysis. Overall, the distribution of self-reported race/ethnicity of women in the CHOICE study were representative of the St. Louis region; few women reported a race other than “black or African-American” (hereafter referred to as “black”) or “white.” Due to small numbers of other groups, only women who reported “black” or “white” race were eligible for inclusion in this sub-study.

Composition of the vaginal microbiota has been previously associated with race.¹ To test whether *Candida* was associated with vaginal niches occupied by particular bacterial communities, we sought a strategy to avoid inadequate representation of less common community types in the different demographic groups so that we would be powered to ask whether *Candida* is associated with particular microbial patterns. We used frequency matching to similarly represent black and white women in each of the three Nugent categories. We used a normal:intermediate:BV ratio of 2:2:1 to ensure that we had samples represented across the Nugent spectrum, while balancing the practical reality that relatively few BV specimens were available from white women. Of the 299 subjects selected, 35 were pregnant at the time of swab collection and excluded from final analysis. Additionally, 9 specimens were excluded due to low bacterial biomass. See Supplemental Methods.

Microbiome analysis and *Candida* colonization status:

DNA was extracted from eluted vaginal swabs and 16S ribosomal profiling of the V4 hypervariable region was performed as described in the Supplemental Methods. The microbiome was classified based on the dominant *Lactobacillus* species present, defined as 50% relative abundance or greater and referred to as, “*L. crispatus*-, *L. iners*-, *L. gasseri*-, or *L. jensenii*-dominant” microbiomes. Communities without a single *Lactobacillus* species reaching 50% were referred to as Diverse communities. A pan-*Candida* qRT-PCR³³ that

amplifies the internally transcribed spacer 1 (ITS1) was used to determine *Candida* colonization status using isolated DNA as template. Prior to analysis we validated this assay among vaginal specimens collected from a second cohort of women enrolled at a different site. See Supplemental Methods for details.

***Candida* growth inhibition:**

Candida strains were grown in yeast extract-peptone-dextrose (YPD) media. *C. albicans* strain SC5314 was obtained from the American Type Culture Collection. Vaginal strains of *Candida* (*C. albicans*: BAT8133, BAT8135, BAT8143, BAT8152, BAT8154, BAT3353A; *C. glabrata*: BAT8139, BAT3353B) were isolated from women as described in the Supplemental Methods. *L. crispatus* (MV-1A-US, JV-V01, MV-3A-US, 125-2-CHN) and *L. iners* (UP II 143-D, Lactin V09V1-C, LEAF 2032-Ad, LEAF 3008-A) strains were obtained from BEI resources and cultured in De Man, Rogosa and Sharpe (MRS) media for 48 hours to make cell free supernatants (CFS). All *Candida* growth inhibition experiments were conducted in 96-well plates. Each well contained a 1:1 ratio of CFS and YPD inoculated with $\sim 10^6$ *C. albicans* colony-forming units (CFU)/mL. YPD was buffered with 300 mM sodium bicarbonate and 300 mM HEPES sodium salt for neutralization assays. For lactic acid growth inhibition assays, fresh MRS was supplemented with racemic lactic acid. A micro pH electrode was used to measure pH of each mixture and lactate was measured with a colorimetric assay. Protonated lactic acid concentrations were calculated using lactate molarity and pH using the Henderson-Hasselbalch equation ($pK_a = 3.9$). See Supplemental Methods for more details about *Candida* growth inhibition experiments.

Statistical analysis:

Statistical analyses and data representation were completed in R (v3.5.1) and Prism (v7). Fisher's Exact Tests (Fisher) were used to assess for associations between cohort characteristics and race, with odds ratios (OR) determined by a conditional maximum likelihood estimate. Unless otherwise noted, we used an extension of the generalized linear model (GLM) method that included race as a potentially confounding covariate to test for associations between cohort characteristics and *Candida* colonization status, using the exponent of the coefficient from the logistic regression to calculate ORs. Note that because *Candida* colonization incidence is $>10\%$ the odds ratios may not be an accurate approximation of the relative risk; see³⁴ for conversion between the two.

We used type-II analysis of variance (ANOVA-II) with Wald test and Tukey's Honestly Significant Different Test (Tukey) to evaluate significance in these models. In instances where multiple statistical tests were performed, we relied on GLM accounting for race. Mann-Whitney tests were used to test for associations with *Candida* abundance and effect size (r) was calculated from the Z value. Statistical tests for *in vitro* experiments included one-way ANOVA with Tukey's correction for multiple comparisons and Mann-Whitney tests as appropriate. Regardless of the statistical method used, P -values < 0.05 were considered significant.

Results

Description of the clinical cohort:

Two-hundred fifty-five non-pregnant women of reproductive age were included in our analysis. In this cohort, 53% of women identified as “white” and 47% identified as “black”. Forty-four (17%) women had BV, while 109 (43%) and 102 (40%) had intermediate and normal vaginal flora respectively. About half of the women (54%) reported using public assistance or having trouble meeting daily needs and were classified as having low socioeconomic status. Body mass index (BMI) was calculated and categorized using standard methods and definitions. Most women (64.3%) reported at least one prior pregnancy. Seventy-two women (28.2%) reported vaginal douching in the last 180 days. Race was found to be associated with socioeconomic status ($p < 0.0001$), BMI ($p = 0.003$), gravidity ($p < 0.0001$) and vaginal douching ($p < 0.0001$). A summary of demographic data and cohort characteristics by race is presented in Supplemental Table 1.

Forty-two (16%) women were vaginally colonized with *Candida*. Of these, most (90%) were colonized by *C. albicans*. *C. glabrata* was less common (~10%). Sequencing of the vaginal microbiome revealed that fifty-two women (20%) had *L. crispatus*-dominant microbiomes, 99 (39%) had *L. iners*-dominant microbiomes and 98 (38%) had microbiomes that were not dominated by a single *Lactobacillus species* (Diverse). We were not powered to test associations between *Candida* and microbiomes dominated by *Lactobacillus jensenii* or *gasseri* since few women ($n=6$) exhibited these microbiomes. Black women were more likely than white women to have *L. iners*-dominant communities (46.7% vs 31.9% Fisher’s Exact; OR = 1.87, 95% CI: 1.10 to 3.14, $p = 0.020$) and less likely to have *L. crispatus*-dominant communities (11.9% vs. 22.1% Fisher’s Exact; OR = 0.380, 95% CI: 0.185 to 0.747, $p = 0.003$).

Associations between *Candida* and cohort characteristics:

Forty-two (16%) women were vaginally colonized with *Candida*. Of these, most (90%) were colonized by *C. albicans*. *C. glabrata* colonization was less common (~10%). Table 1 contains a summary of *Candida* status by sociodemographic and other cohort characteristics. Only race was significantly correlated with vaginal *Candida*; black women were more likely to be colonized compared to white women (OR = 2.05, 95% CI: 1.03 to 4.25, Fisher’s Exact, $p = 0.042$). Based on these findings, race was considered to be a potential confounder and incorporated into subsequent analyses using generalized linear models (GLM) to evaluate factors associated with *Candida* colonization.

Associations between *Candida* and cohort characteristics

Candida colonization rates did not differ based on Nugent-defined BV status (GLM; ANOVA-II, $p = 0.897$). We did not find any association between a woman’s socioeconomic status and vaginal *Candida* colonization. *Candida* colonization did not differ significantly among underweight (20% *Candida*), normal weight (18%) and overweight (23%) women. However, obese women were less likely to be colonized compared to non-obese women (GLM; OR = 0.322, 95% CI: 0.123 to 0.744; Tukey’s HSD, $p = 0.013$, see Supplement for

comment). Women reporting current use of hormonal contraceptives containing estrogen and progestin were *Candida*-colonized at higher rates than women reporting non-hormonal methods, although this did not reach statistical significance (GLM; OR = 1.77, 95% CI: 0.858 to 3.58; Tukey's HSD, $p = 0.237$, see Supplement for details). Women who reported vaginal douching in the last 180 days were less likely to be *Candida* positive compared to women who reported no vaginal douching (GLM; OR = 0.364, 95% CI: 0.143 to 0.838; Tukey's HSD, $p = 0.047$).

Relationships between *Candida* colonization and the vaginal microbiome:

Next, we investigated relationships between *Candida* colonization and dominant members of the vaginal microbiome based on 16S ribosomal gene profiling. *Candida* prevalence did not differ between *Lactobacillus* dominated (50% or greater *Lactobacillus*) and non-*Lactobacillus* dominated microbiomes (GLM; ANOVA-II, $p = 0.327$). Although the absolute abundance of *Candida* as measured by qPCR did not differ within *L. iners*-dominant communities compared to other community types (Mann-Whitney, $r = 0.046$, $p = 0.617$), *L. iners*-dominant communities were more likely to harbor *Candida* than non-*L. iners*-dominant communities (GLM; OR = 2.00, 95% CI: 1.02 to 3.98; Tukey's HSD, $p = 0.045$; see supplemental Table 2). Further analysis specifically showed that *L. iners*-dominant communities were more likely to be colonized than *L. crispatus*-dominant communities (OR = 2.85, 95% CI: 1.03 to 7.21; Fisher's Exact, $p = 0.048$). Among *Candida* positive women, higher levels of *Candida* (by qRT-PCR) were observed among black women compared to white women, although not statistically significant (Mann-Whitney test, $r = 0.173$, $p = 0.131$).

In vitro studies: inhibition of *Candida* growth by lactobacilli:

Both *L. crispatus* and lactic acid have been shown to thwart the growth of *C. albicans*.^{35–37} Next, we compared the inhibitory potential of *L. crispatus* and *L. iners* on *Candida* growth *in vitro*. *C. albicans* was cultured together with cell free supernatants (CFS) from *L. crispatus* and *L. iners* (8 strains total), followed by *Candida* CFU enumeration. Compared to *L. iners* CFS, *L. crispatus* CFS resulted in lower pH (pH = 4.0 vs. pH = 4.6, $p < 0.0001$) and correspondingly higher levels of protonated lactic acid in CFS-YPD (55 mM vs. 11 mM, $p < 0.0001$) (Figure 2). Buffering CFS-YPD to a neutral pH reduced levels of protonated lactic acid to below appreciable levels, ablated *Candida* growth inhibition, and eliminated the difference in *C. albicans* growth observed between *L. crispatus* and *L. iners* (Figure 2). Further, lactic acid was sufficient to inhibit *Candida* growth. In particular, significantly more growth inhibition was observed at 49 mM protonated lactic acid compared to 11 mM, levels comparable to the *L. crispatus* and *L. iners* CFS-YPD respectively. Similar findings were seen using vaginal isolates of *C. albicans*. In contrast, *C. glabrata* exhibited only modest growth inhibition (Figure 2). Together, these data suggest that lactic acid is both necessary and sufficient for growth inhibition of *C. albicans in vitro*.

Comment

Principal Findings:

We demonstrate that *Candida* colonization is associated with characteristics of the vaginal microbiome (dominance of *L. iners* compared to *L. crispatus*). Results in clinical specimens are consistent with *in vitro* data, which show that *L. crispatus* produces a pH-dependent factor that inhibits *C. albicans* growth more effectively compared to secreted factors of *L. iners* grown under the same conditions.

Results:

As a relatively common vaginal microbial community member, *Candida* may influence reproductive health. Previous studies suggested vaginal *Lactobacillus* colonization as a risk factor for *Candida* colonization or VVC,^{5,6,17} but seem inconsistent with other reports of *Candida*-bacteria associations.^{18–21} Here we provide more taxonomic resolution, showing that that not all *Lactobacillus*-dominant communities are equally associated with *Candida* colonization.

Clinical Implications:

Clinicians often group all lactobacilli together. This study adds to the growing body of evidence suggesting that *L. iners*-dominant communities are more permissive to vaginal colonization with potential pathogens, including *Candida*.

Research Implications:

Of interest, black race was associated with obesity and vaginal douching as in prior studies. But surprisingly, the correlation between *Candida* and black race cannot be accounted for by obesity or douching because obese women and those who douche were actually *less* likely to be colonized with *Candida* (OR = 0.322 and 0.364 respectively). The literature contains inconsistent reports regarding the role of *Lactobacillus* colonization as a risk factor for *Candida* colonization or VVC.^{5,6,17,18–21} We show that that not all *Lactobacillus*-dominant communities are equally associated with *Candida*. *In vitro* data provide one possible explanation, showing that *L. iners* strains do not produce the same magnitude of lactic acid compared to *L. crispatus* strains. An alternative, albeit not mutually exclusive explanation, is that vaginal *Candida* colonization may shift the microbiome to favor *L. iners*.

Interestingly, we observed similar rates of *Candida* colonization in *L. crispatus*-dominant and Diverse communities. With fewer lactic acid producing bacteria present, the vaginal pH of women with Diverse microbiome is less acidic.¹ These findings indicate that Diverse communities resist *Candida* by lactic acid-independent mechanisms.

Additional studies are needed to evaluate potential mechanisms governing these relationships and apply these findings in clinical settings.

Strengths and Limitations:

Key strengths of our study design were the validation of a *Candida*-specific qPCR assay³³ for laboratory testing for *Candida* colonization, offering flexibility in settings where archived

frozen vaginal swabs are more practical. We acknowledge that the specimens selected for this study are not a naturalistic representation of vaginal microbiomes. Rather, the frequency matching of black and white women across the Nugent spectrum is a strength that enabled power to test associations between yeast and bacteria in different racial groups. Limitations include: 1) the sample size and number of *Candida*-positive women were relatively small, limiting power to model multiple potential confounders, 2) this cohort may not be representative of the U.S. population, 3) clinical data were not available to examine the relationship between *Candida* colonization and VVC, and 4) our *in vitro* findings may not be representative of *in vivo* relationships.

Conclusion:

These data suggest that *L. iners*-dominant vaginal communities may support the co-occurrence of *Candida*.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements:

We thank the Contraceptive CHOICE Project support staff and Jennifer Reed (née Bick, Washington University) for Nugent scoring. We appreciate Dr. Sharon Hillier for verifying Nugent scoring. We also thank Denise Spear WHNP-BC, Valerie Higginbotham WHNP-BC (St. Louis County Department of Public Health) and Courtney Amegashie (Washington University, NIH funding) for collection and swab processing and the St. Louis County Department of Public Health for facilitating sample collection used to validate the *Candida* qPCR assay. We thank Andrew Kau for advice (Washington University, in part NIH funding) on microbiome profiling and Deborah Frank (Washington University) for editorial input. Finally, we appreciate those who provided vaginal samples.

Source of funding: Funding for the Contraceptive CHOICE Project was provided by an anonymous foundation. This study was supported in part by a March of Dimes grant (Prematurity Research Center) and a pilot grant from the same (ALL). Funding was provided by a pilot grant from the Center for Women's Infectious Disease Research (JCF) and by the NIH: R01 AI114635 (ALL and WGL), R01 AI127554 (WGL), and by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the NIH: F30HD094435 (BAT). The sponsors had no role in the study design, the collection, analysis or interpretation of data, or the decision to submit the article for publication. The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References:

1. Ravel J, Gajer P, Abdo Z, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A. 2011;108 Suppl 1:4680–4687. [PubMed: 20534435]
2. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. Microbiology. 2014;160(Pt 10):2272–2282. [PubMed: 25073854]
3. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29(2):297–301. [PubMed: 1706728]
4. Anahtar MN, Gootenberg DB, Mitchell CM, Kwon DS. Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell Host Microbe. 2018;23(2):159–168. [PubMed: 29447695]
5. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in nonpregnant women: a longitudinal study. Obstet Gynecol. 2004;104(5 Pt 1):926–930. [PubMed: 15516380]

6. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy *Candida* colonization during pregnancy. Vaginal Infections and Prematurity Study Group. *Am J Obstet Gynecol*. 1998;178(2):374–380. [PubMed: 9500502]
7. Brandolt TM, Klafke GB, Goncalves CV, et al. Prevalence of *Candida* spp. in cervical-vaginal samples and the *in vitro* susceptibility of isolates. *Braz J Microbiol*. 2017;48(1):145–150. [PubMed: 27756539]
8. Payne MS, Ireland DJ, Watts R, et al. *Ureaplasma parvum* genotype, combined vaginal colonisation with *Candida albicans*, and spontaneous preterm birth in an Australian cohort of pregnant women. *BMC Pregnancy Childbirth*. 2016;16(1):312. [PubMed: 27756249]
9. Payne MS, Cullinane M, Garland SM, et al. Detection of *Candida* spp. in the vagina of a cohort of nulliparous pregnant women by culture and molecular methods: Is there an association between maternal vaginal and infant oral colonisation? *Aust N Z J Obstet Gynaecol*. 2016;56(2):179–184. [PubMed: 26437337]
10. Fidel PL Jr., Barousse M, Espinosa T, et al. An intravaginal live *Candida* challenge in humans leads to new hypotheses for the immunopathogenesis of vulvovaginal candidiasis. *Infect Immun*. 2004;72(5):2939–2946. [PubMed: 15102806]
11. Maki Y, Fujisaki M, Sato Y, Sameshima H. *Candida* Chorioamnionitis Leads to Preterm Birth and Adverse Fetal-Neonatal Outcome. *Infect Dis Obstet Gynecol*. 2017;2017:9060138. [PubMed: 29180840]
12. To V, Gurberg J, Krishnamurthy S. Tubo-Ovarian Abscess Caused by *Candida albicans* in an Obese Patient. *J Obstet Gynaecol Can*. 2015;37(5):426–429. [PubMed: 26168103]
13. Menon S, Broeck DV, Rossi R, Ogbe E, Harmon S, Mabeya H. Associations Between Vaginal Infections and Potential High-risk and High-risk Human Papillomavirus Genotypes in Female Sex Workers in Western Kenya. *Clin Ther*. 2016;38(12):2567–2577. [PubMed: 27836494]
14. Holzer I, Farr A, Kiss H, Hagmann M, Petricevic L. The colonization with *Candida* species is more harmful in the second trimester of pregnancy. *Arch Gynecol Obstet*. 2017;295(4):891–895. [PubMed: 28255766]
15. Farr A, Kiss H, Holzer I, Husslein P, Hagmann M, Petricevic L. Effect of asymptomatic vaginal colonization with *Candida albicans* on pregnancy outcome. *Acta Obstet Gynecol Scand*. 2015;94(9):989–996. [PubMed: 26084843]
16. Babu G, Singaravelu BG, Srikumar R, Reddy SV, Kokan A. Comparative Study on the Vaginal Flora and Incidence of Asymptomatic Vaginosis among Healthy Women and in Women with Infertility Problems of Reproductive Age. *J Clin Diagn Res*. 2017;11(8):DC18–DC22.
17. McClelland RS, Richardson BA, Hassan WM, et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. *J Infect Dis*. 2009;199(12):1883–1890. [PubMed: 19456235]
18. Gonzalez-Fernandez D, Koski KG, Sinisterra OT, Del Carmen Pons E, Murillo E, Scott ME. Interactions among urogenital, intestinal, skin, and oral infections in pregnant and lactating Panamanian Ngabe women: a neglected public health challenge. *Am J Trop Med Hyg*. 2015;92(6):1100–1110. [PubMed: 25825387]
19. Liu MB, Xu SR, He Y, et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. *PLoS One*. 2013;8(11):e79812. [PubMed: 24265786]
20. Vahidnia A, Tuin H, Blikendaal H, Spaargaren J. Association of sexually transmitted infections, *Candida* species, Gram-positive flora and perianal flora with bacterial vaginosis. *New Microbiol*. 2015;38(4):559–563. [PubMed: 26485014]
21. Rathod SD, Klausner JD, Krupp K, Reingold AL, Madhivanan P. Epidemiologic features of Vulvovaginal Candidiasis among reproductive-age women in India. *Infect Dis Obstet Gynecol*. 2012;2012:859071. [PubMed: 23118494]
22. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. *N Engl J Med*. 2005;353(18):1899–1911. [PubMed: 16267321]
23. Fredricks DN. Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. *Anaerobe*. 2011;17(4):191–195. [PubMed: 21376827]
24. Rampersaud R, Lewis EL, LaRocca TJ, Ratner AJ. Environmental pH modulates inerolysin activity via post-binding blockade. *Sci Rep*. 2018;8(1):1542. [PubMed: 29367601]

25. Rampersaud R, Planet PJ, Randis TM, et al. Inerolysin, a cholesterol-dependent cytolysin produced by *Lactobacillus iners*. *J Bacteriol.* 2011;193(5):1034–1041. [PubMed: 21169489]
26. van Houdt R, Ma B, Bruisten SM, Speksnijder A, Ravel J, de Vries HJC. *Lactobacillus iners*-dominated vaginal microbiota is associated with increased susceptibility to *Chlamydia trachomatis* infection in Dutch women: a case-control study. *Sex Transm Infect.* 2018;94(2):117–123. [PubMed: 28947665]
27. Muzny CA, Blanchard E, Taylor CM, et al. Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study. *J Infect Dis.* 2018;218(6):966–978. [PubMed: 29718358]
28. Nunn KL, Wang YY, Harit D, et al. Enhanced Trapping of HIV-1 by Human Cervicovaginal Mucus Is Associated with *Lactobacillus crispatus*-Dominant Microbiota. *MBio.* 2015;6(5):e01084–01015. [PubMed: 26443453]
29. Joag V, Obila O, Gajer P, et al. Impact of Standard Bacterial Vaginosis Treatment on the Genital Microbiota, Immune Milieu, and Ex Vivo Human Immunodeficiency Virus Susceptibility. *Clin Infect Dis.* 2018.
30. Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. *Am J Obstet Gynecol.* 2010;203(2):115 e111–117. [PubMed: 20541171]
31. Lewis WG, Robinson LS, Perry J, et al. Hydrolysis of secreted sialoglycoprotein immunoglobulin A (IgA) in ex vivo and biochemical models of bacterial vaginosis. *J Biol Chem.* 2012;287(3):2079–2089. [PubMed: 22134918]
32. Amegashie CP, Gilbert NM, Peipert JF, Allsworth JE, Lewis WG, Lewis AL. Relationship between Nugent score and vaginal epithelial exfoliation. *PLoS One.* 2017;12(5):e0177797. [PubMed: 28562623]
33. Zhang J, Hung GC, Nagamine K, Li B, Tsai S, Lo SC. Development of *Candida*-Specific Real-Time PCR Assays for the Detection and Identification of Eight Medically Important *Candida* Species. *Microbiol Insights.* 2016;9:21–28. [PubMed: 27103821]
34. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. *JAMA.* 1998;280(19):1690–1691. [PubMed: 9832001]
35. Krasner RI, Young G, Yudkofsky PL. Interactions of oral strains of *Candida albicans* and lactobacilli. *J Bacteriol.* 1956;72(4):525–529. [PubMed: 13366958]
36. Wang S, Wang Q, Yang E, Yan L, Li T, Zhuang H. Antimicrobial Compounds Produced by Vaginal *Lactobacillus crispatus* are able to Strongly Inhibit *Candida albicans* Growth, Hyphal Formation and Regulate Virulence-related Gene Expressions. *Front Microbiol.* 2017;8:564. [PubMed: 28421058]
37. Parolin C, Marangoni A, Laghi L, et al. Isolation of Vaginal lactobacilli and Characterization of Anti-*Candida* Activity. *PLoS One.* 2015;10(6):e0131220. [PubMed: 26098675]
38. Kau AL, Planer JD, Liu J, et al. Functional characterization of IgA-targeted bacterial taxa from undernourished Malawian children that produce diet-dependent enteropathy. *Sci Transl Med.* 2015;7(276):276ra224.
39. Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. *Science.* 2013;341(6150):1241214. [PubMed: 24009397]
40. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001–2004; associations with symptoms, sexual behaviors, and reproductive health. *Sex Transm Dis.* 2007;34(11):864–869. [PubMed: 17621244]
41. Brookheart RT, Lewis WG, Peipert JF, Lewis AL, Allsworth JE. Association between obesity and bacterial vaginosis as assessed by Nugent score. *Am J Obstet Gynecol.* 2019.
42. Si J, You HJ, Yu J, Sung J, Ko G. *Prevotella* as a Hub for Vaginal Microbiota under the Influence of Host Genetics and Their Association with Obesity. *Cell Host Microbe.* 2017;21(1):97–105. [PubMed: 28017660]
43. Marrazzo JM, Fiedler TL, Srinivasan S, et al. Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. *J Infect Dis.* 2012;205(10):1580–1588. [PubMed: 22448002]

AJOG at a Glance:

- A.** The purpose of the study was to characterize the relationship between the composition of the vaginal microbiome and *Candida* colonization among non-pregnant women.
- B.** Women with *Lactobacillus iners*-dominant microbiomes were more likely to harbor *Candida* than women with *Lactobacillus crispatus*-dominant microbiomes. *In vitro* data suggests higher production of lactic acid by *Lactobacillus crispatus* compared to *Lactobacillus iners* may contribute to differential anti-*Candida* activity. Neutralization of pH eliminated the anti-*Candida* activity secreted by lactobacilli.
- C.** Consideration of *Candida* as part of the vaginal microbiome may have utility for understanding different relationships between vaginal microbiome and adverse outcomes.




Figure 1: Heatmap of all samples in the cohort clustered by community type. Heat map of samples clustered by community type showing the top 25 taxa observed across the cohort. The bars above the heatmap indicate community type, BV status by Nugent score, race and *Candida* status. In the heat map, *light blue* indicates the highest abundance, *darker blues* indicate lower abundance and *black* indicates very low abundance or not present. Black race ($p = 0.037$) and *L. iners*-dominant communities ($p = 0.045$) were associated with *Candida* colonization.




Figure 2: In vitro inhibition of *Candida* by *Lactobacillus* CFS and lactic acid.

A-B, Characterization of *Candida* growth medium supplemented with *Lactobacillus* CFS (YPD-CFS) in native and buffered states from four *L. crispatus* and four *L. iners* strains, prior to *Candida* inoculation. **A**, pH of YPD-CFS; **B**, Concentration of protonated lactic acid in YPD-CFS; **C**, Growth inhibition of *Candida* laboratory strain SC5314, showing three technical replicates for each *Lactobacillus* YPD-CFS. Analysis by one-way ANOVA with Tukey’s correction for multiple comparisons. **D-F**, Characterization of the inhibitory effect of lactic acid supplemented medium on *Candida* growth. Three technical replicates from two biological experiments are shown. **D**, Growth inhibition of SC5314 by lactic acid showing Mann-Whitney test comparison of 11 mM to 49 mM protonated lactic acid; **E**, Lactic acid growth inhibition of 6 vaginal *C. albicans* isolates; **F**, Lactic acid growth inhibition of 2

vaginal *C. glabrata* isolates. Data points in panel D reflect 6 replicates from two experiments for each condition. Error bars in E-F show the standard deviation from the mean of three replicates for each isolate. Approximate starting inoculum for growth assays is indicated by a dashed line. Statistical significance: ns (not significant), * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.0001$.

Table 1:Characteristics of subjects with vaginal *Candida* compared with those without vaginal *Candida*.

Characteristics	Total Cohort	<i>Candida</i> Positive	<i>Candida</i> Negative	P-value
Total Number of Subjects	255	42 (16.5)	213 (83.5)	
Age				0.811
< 20	28 (11.0)	6 (14.3)	22 (10.3)	
20 to 29	178 (69.8)	29 (69.0)	149 (70.0)	
30 to 39	44 (17.3)	7 (16.7)	37 (17.4)	
40 +	5 (2.0)	0 (0.0)	5 (2.3)	
Race				0.042
Black	120 (47.1)	26 (61.9)	94 (44.1)	
White	135 (52.9)	16 (38.1)	119 (55.9)	
Nugent-defined Vaginal Flora				0.833
Normal	102 (40.0)	15 (35.7)	87 (40.8)	
Intermediate	109 (42.7)	19 (45.2)	90 (42.3)	
BV	44 (17.3)	8 (19.0)	36 (16.9)	
Socioeconomic Status (SES)				1
Low SES	138 (54.1)	23 (54.8)	115 (54.0)	
Not Low SES	117 (45.9)	19 (45.2)	98 (46.0)	
Body Mass Index (kg/m ²)				0.127
Underweight (< 18.5)	15 (5.9)	3 (7.1)	12 (5.6)	
Normal Weight (18.5 – 24.9)	103 (40.4)	19 (45.2)	84 (39.4)	
Overweight (25 – 30)	48 (18.8)	11 (26.2)	37 (17.4)	
Obese (> 30)	78 (30.6)	7 (16.7)	71 (33.3)	
Not Documented	11 (4.3)	2 (4.8)	9 (4.2)	
Current Birth Control Method				0.320
Estrogen + Progestin ^a	72 (28.2)	16 (38.1)	56 (26.3)	
Progestin ^b	12 (4.7)	1(2.4)	11 (5.2)	
Non-Hormonal ^c	171 (67.1)	25 (59.5)	146 (68.5)	
Vaginal Douching in Last 180 Days				0.323
Yes	72 (28.2)	8 (19.0)	64 (30.0)	
No	182 (71.4)	34 (81.0)	148 (69.5)	
Don't Know	1 (0.4)	0 (0.0)	1 (0.5)	
Gravidity				0.160
None	91 (35.7)	15 (35.7)	76 (35.7)	
1	58 (22.7)	6 (14.3)	52 (24.4)	
2	47 (18.4)	6 (14.3)	41 (19.2)	
3+	59 (23.1)	15 (35.7)	44 (20.7)	
Community Type				0.113

Characteristics	Total Cohort	<i>Candida</i> Positive	<i>Candida</i> Negative	P-value
<i>L. crispatus</i> -dominant	52 (20.4)	5 (11.9)	47 (22.1)	
<i>L. iners</i> -dominant	99 (38.8)	23 (54.8)	76 (35.7)	
<i>L. jensenii</i> -dominant	3 (1.2)	1 (2.4)	2 (0.9)	
<i>L. gasseri</i> -dominant	3 (1.2)	0 (0.0)	3 (1.4)	
Diverse	98 (38.4)	13 (31.0)	85 (39.9)	

Values are n (%). Fisher's Exact Tests were used to determine p-values for each set of variables without adjusting for race. Note that p-values given in the text use GLM (accounting for race as a potential confounder).

^aWomen who reported the oral contraceptive pill or the birth control ring;

^bWomen who reported the levonorgestrel-containing intrauterine device or depot medroxyprogesterone acetate;

^cWomen who reported condoms, rhythm/natural family planning, abstinence, withdrawal or nothing.